by Kelley Tracy | Mar 3, 2021 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase II STTR Grant Entitled “Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Virus” Doylestown, PA. March 3, 2021 – FCCDC is pleased to announce that...
by Kelley Tracy | Jul 17, 2020 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I SBIR Grant Entitled “Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle” Doylestown, PA. July 17, 2020 – FCCDC is pleased to announce...
by Kelley Tracy | Jun 22, 2020 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I STTR Grant Entitled “PROTACS Against Nef as a Functional Cure for HIV Infection” Doylestown, PA. June 22, 2020 – FCCDC is pleased to announce it has been awarded a...
by Kelley Tracy | Apr 3, 2020 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I STTR Grant Entitled “Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis” Doylestown, PA. April 3, 2020 – FCCDC is pleased...
by Kelley Tracy | Sep 11, 2019 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Three Year Phase IIB Grant Entitled “Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT” Doylestown, PA. September 11, 2019 – FCCDC is pleased to...
by Kelley Tracy | Aug 21, 2019 | Uncategorized
The Fox Chase Chemical Diversity Center Announces Troriluzole is in Clinical Trials for the Treatment of Alzheimer’s Doylestown, PA. August 21, 2019 – Troriluzole was designed and prepared at FCCDC funded originally by two SBIR grants from the...
